沃华医药(002107) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥235,281,203.05, a decrease of 9.29% compared to ¥259,375,844.83 in the same period last year[5] - Net profit attributable to shareholders was ¥25,449,286.76, down 5.35% from ¥26,888,553.37 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 235,281,203.05, a decrease of 9.4% compared to CNY 259,375,844.83 in the same period last year[17] - Net profit for Q1 2023 was CNY 22,231,890.00, slightly down from CNY 22,912,438.15 in Q1 2022, representing a decrease of 3.0%[18] - The total comprehensive income attributable to the parent company was CNY 25,449,286.76, a decrease from CNY 26,888,553.37 in the previous period, representing a decline of approximately 5.34%[22] Cash Flow - The net cash flow from operating activities decreased by 36.18%, amounting to ¥31,206,904.28 compared to ¥48,896,554.00 in the previous year[5] - The net cash flow from operating activities was CNY 31,206,904.28, down from CNY 48,896,554.00 in the previous period, indicating a decrease of about 36.3%[20] - The cash inflow from operating activities totaled CNY 275,294,182.68, compared to CNY 278,874,679.77 in the previous period, reflecting a slight decrease of approximately 1.04%[20] - The cash outflow from operating activities was CNY 244,087,278.40, an increase from CNY 229,978,125.77 in the previous period, which is an increase of about 6.1%[20] - The net cash flow from investing activities was -CNY 589,405.82, improving from -CNY 1,900,205.62 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,104,442,553.60, reflecting a slight increase of 0.40% from ¥1,099,991,311.86 at the end of the previous year[5] - Total assets increased to CNY 1,104,442,553.60 from CNY 1,099,991,311.86, showing a growth of 0.4%[15] - Total liabilities decreased to CNY 292,420,182.25 from CNY 310,200,830.51, a decline of 5.7%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 44,473[10] - Basic and diluted earnings per share were both ¥0.04, representing a decline of 20.00% from ¥0.05 in the same period last year[5] - Basic and diluted earnings per share were both CNY 0.04, down from CNY 0.05 in the previous period, indicating a decrease of 20%[22] Expenses - Management expenses rose by 31.67% to ¥18,772,532.32 due to increased personnel costs[9] - Total operating costs for Q1 2023 were CNY 212,158,583.49, down 8.2% from CNY 231,011,940.52 year-on-year[17] - The company reported a significant reduction in sales expenses to CNY 117,466,712.37 from CNY 133,691,504.63, a decrease of 12.1%[17] - The company’s R&D expenses increased to CNY 15,552,459.72 from CNY 14,040,887.58, reflecting a growth of 10.8%[17] Cash and Equivalents - The company's cash and cash equivalents increased to CNY 309,845,793.94 from CNY 278,289,264.27 at the beginning of the year, reflecting a growth of 11.4%[14] - The cash and cash equivalents at the end of the period were CNY 307,633,936.01, an increase from CNY 223,135,070.87 at the end of the previous period, representing a growth of approximately 37.9%[22]